DE69326145T2 - Synthetische peptide für die behandlung von myasthenia gravis - Google Patents
Synthetische peptide für die behandlung von myasthenia gravisInfo
- Publication number
- DE69326145T2 DE69326145T2 DE69326145T DE69326145T DE69326145T2 DE 69326145 T2 DE69326145 T2 DE 69326145T2 DE 69326145 T DE69326145 T DE 69326145T DE 69326145 T DE69326145 T DE 69326145T DE 69326145 T2 DE69326145 T2 DE 69326145T2
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- myasthenia gravis
- peptides
- amino acid
- synthetic peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 206010028417 myasthenia gravis Diseases 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 108010009685 Cholinergic Receptors Proteins 0.000 abstract 1
- 102000034337 acetylcholine receptors Human genes 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 abstract 1
- 230000009696 proliferative response Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90039392A | 1992-06-18 | 1992-06-18 | |
| PCT/US1993/005906 WO1994000148A1 (en) | 1992-06-18 | 1993-06-18 | Synthetic peptides for the treatment of myasthenia gravis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69326145D1 DE69326145D1 (de) | 1999-09-30 |
| DE69326145T2 true DE69326145T2 (de) | 2000-04-27 |
Family
ID=25412446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69326145T Expired - Fee Related DE69326145T2 (de) | 1992-06-18 | 1993-06-18 | Synthetische peptide für die behandlung von myasthenia gravis |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0646016B1 (de) |
| JP (1) | JP3996635B2 (de) |
| AT (1) | ATE183652T1 (de) |
| AU (1) | AU678372B2 (de) |
| CA (1) | CA2138258C (de) |
| DE (1) | DE69326145T2 (de) |
| DK (1) | DK0646016T3 (de) |
| ES (1) | ES2139667T3 (de) |
| GR (1) | GR3031371T3 (de) |
| IL (3) | IL122445A (de) |
| WO (1) | WO1994000148A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6066621A (en) * | 1989-12-10 | 2000-05-23 | Yeda Research And Development Co. Ltd. | Synthetic peptides for the treatment of myasthenia gravis |
| US5843462A (en) * | 1995-11-30 | 1998-12-01 | Regents Of The University Of Minnesota | Diphtheria toxin epitopes |
| WO1999030736A2 (en) | 1997-12-16 | 1999-06-24 | Regents Of The University Of Minnesota | Methods to treat undesirable immune responses |
| AU766498B2 (en) | 1998-07-23 | 2003-10-16 | President And Fellows Of Harvard College, The | Synthetic peptides and methods of use for autoimmune disease therapies |
| EP4352090A2 (de) | 2021-06-07 | 2024-04-17 | Toleranzia AB | Fusionsprotein zur behandlung von myasthenia gravis |
-
1993
- 1993-06-18 ES ES93916644T patent/ES2139667T3/es not_active Expired - Lifetime
- 1993-06-18 JP JP50250294A patent/JP3996635B2/ja not_active Expired - Fee Related
- 1993-06-18 EP EP93916644A patent/EP0646016B1/de not_active Expired - Lifetime
- 1993-06-18 IL IL12244593A patent/IL122445A/xx not_active IP Right Cessation
- 1993-06-18 IL IL12244597A patent/IL122445A0/xx unknown
- 1993-06-18 AT AT93916644T patent/ATE183652T1/de not_active IP Right Cessation
- 1993-06-18 DK DK93916644T patent/DK0646016T3/da active
- 1993-06-18 IL IL10606593A patent/IL106065A/en not_active IP Right Cessation
- 1993-06-18 CA CA002138258A patent/CA2138258C/en not_active Expired - Fee Related
- 1993-06-18 DE DE69326145T patent/DE69326145T2/de not_active Expired - Fee Related
- 1993-06-18 WO PCT/US1993/005906 patent/WO1994000148A1/en active IP Right Grant
- 1993-06-18 AU AU46429/93A patent/AU678372B2/en not_active Ceased
-
1999
- 1999-09-29 GR GR990402465T patent/GR3031371T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2138258A1 (en) | 1994-01-06 |
| JP3996635B2 (ja) | 2007-10-24 |
| IL106065A0 (en) | 1993-10-20 |
| DE69326145D1 (de) | 1999-09-30 |
| DK0646016T3 (da) | 2000-03-20 |
| ES2139667T3 (es) | 2000-02-16 |
| AU678372B2 (en) | 1997-05-29 |
| IL106065A (en) | 1999-10-28 |
| IL122445A (en) | 2000-08-31 |
| WO1994000148A1 (en) | 1994-01-06 |
| ATE183652T1 (de) | 1999-09-15 |
| EP0646016A1 (de) | 1995-04-05 |
| EP0646016A4 (de) | 1995-07-12 |
| IL122445A0 (en) | 1998-06-15 |
| GR3031371T3 (en) | 2000-01-31 |
| CA2138258C (en) | 2003-08-19 |
| JPH07508521A (ja) | 1995-09-21 |
| AU4642993A (en) | 1994-01-24 |
| EP0646016B1 (de) | 1999-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE108662T1 (de) | Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus. | |
| ATE260295T1 (de) | Peptidfragmente von mikrobiellen stressproteinen und daraus hergestellte pharmazeutische zusammensetzungen für die behandlung und vorbeugung von entzündungserkrankungen | |
| NO873699D0 (no) | Polypeptid som er egnet til dempning, behandling og diagnosering av autoimmune lidelser saasom leddbetennelser. | |
| CA2208274A1 (en) | Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes | |
| DK0687180T3 (da) | Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti | |
| ATE183652T1 (de) | Synthetische peptide für die behandlung von myasthenia gravis | |
| NO963487L (no) | Isolerte, tyrosinaseavledete peptider, samt anvendelser derav | |
| DE69607962T2 (de) | Synthetische peptide und diese enthaltende pharmazeutische zusammensetzungen | |
| WO1992021697A3 (en) | Diagnostic peptides derived from m.tuberculosis antigens | |
| DK0764273T3 (da) | Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose | |
| DE3887053T2 (de) | Stlv-iii-verwandte polypeptide, diagnosesysteme und testmethoden. | |
| NO971517D0 (no) | Peptider og farmasöytiske sammensetninger omfattende dem | |
| DE3886032T2 (de) | Hiv-1-verwandte polypeptide, diagnosesysteme und testverfahren. | |
| NO900255L (no) | Peptider med t-cellehjelperaktivitet. | |
| RU93005016A (ru) | Иммунорегуляторные и нейрорегуляторные пентапептиды, фармацевтические композиции на их основе, способ получения пентапептидов, способ лечения | |
| MX9800191A (es) | Peptidos novedosos derivados de proteina humana 60 producida por choque termico, para tratamiento de diabetes, composiciones, metodos y equipos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |